Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.

MLA

Harris, J.Kirk, et al. “Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.” Annals of the American Thoracic Society, vol. 17, no. 2, Feb. 2020, pp. 212–20. EBSCOhost, https://doi.org/10.1513/AnnalsATS.201907-493OC.

APA

Harris, J. K., Wagner, B. D., Zemanick, E. T., Robertson, C. E., Stevens, M. J., Heltshe, S. L., Rowe, S. M., & Sagel, S. D. (2020). Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Annals of the American Thoracic Society, 17(2), 212–220. https://doi.org/10.1513/AnnalsATS.201907-493OC

Chicago

Harris, J Kirk, Brandie D Wagner, Edith T Zemanick, Charles E Robertson, Mark J Stevens, Sonya L Heltshe, Steven M Rowe, and Scott D Sagel. 2020. “Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.” Annals of the American Thoracic Society 17 (2): 212–20. doi:10.1513/AnnalsATS.201907-493OC.